Biogen Idec’s Commitment to MS Demonstrated Through Significant Scientific Data Being Presented at the 28th ECTRIMS

WESTON, Mass.--(BUSINESS WIRE)--

Biogen Idec (BIIB) will have extensive data from the companys leading multiple sclerosis (MS) franchise presented during the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10 13. Fifty-three poster and platform presentations will further showcase Biogen Idecs commitment to advancing the treatment of MS and improving the lives of people living with the disease around the world.

For nearly 20 years, Biogen Idec has had a steadfast commitment to the MS community. This began with the approval of AVONEX and then TYSABRI, and continues today with the global regulatory submissions for oral dimethyl fumarate, said Alfred Sandrock, M.D., Ph.D., senior vice president, development sciences and chief medical officer, Biogen Idec. Our continued dedication to the advancement of MS treatment is evident in our pipeline, which is the deepest in the industry. Though significant advances have been made, we will not rest while there is so much more we can do to improve the lives of those living with MS.

Data from the Biogen Idec MS Pipeline Key scientific highlights being presented during ECTRIMS from the companys pipeline will include analyses of pooled data from the Phase 3 DEFINE and CONFIRM clinical trials of oral dimethyl fumarate (BG-12), primary results from the daclizumab high-yield process (DAC HYP) SELECTION study, and early-stage research showing the results of a study of anti-LINGO 1 (BIIB033) in optic nerve damage in animal models.

Dimethyl Fumarate Dimethyl fumarate has been studied as an oral agent for MS and is currently under regulatory review in the United States, European Union, Switzerland, Australia and Canada for the treatment of MS. Detailed data from the programs two Phase 3 clinical trials, DEFINE and CONFIRM, were recently published in The New England Journal of Medicine. There will be 14 posters, one platform presentation and one late breaking news poster presented. Highlights include:

DAC HYP DAC HYP is an investigational, once-monthly subcutaneous therapy that is in Phase 3 clinical development for the treatment of RRMS. Five DAC HYP posters will be presented, along with one late breaking news platform presentation of the primary results from the SELECTION study, a randomized, double-blind extension study designed to assess sustained efficacy and safety of DAC HYP in the second year of treatment. Highlights include:

Anti-LINGO 1 Anti-LINGO 1 is a monoclonal antibody in early stage clinical trials. Previous data from animal models have shown that it promotes remyelination and axon survival. Proof of concept studies in optic neuritis are expected to start in the fourth quarter of this year, and during the second half of 2013 for MS. Two company-sponsored anti-LINGO 1 posters will be presented at the Congress:

Data from the Biogen Idec MS Franchise

TYSABRI TYSABRI is approved in the United States for relapsing forms of MS and in the European Union for RRMS. There will be 10 company- and partner-sponsored TYSABRI posters and one platform presentation. Highlights include:

AVONEX AVONEX is one of the most prescribed treatments for relapsing forms of MS worldwide. AVONEX PEN, the first intramuscular autoinjector approved for MS, is available in the United States and European Union for those choosing AVONEX to treat their MS. Ten AVONEX posters will be presented. Highlights include:

Visit link:
Biogen Idec’s Commitment to MS Demonstrated Through Significant Scientific Data Being Presented at the 28th ECTRIMS